Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays

Gynecologic Oncology

Volumn 110, Issue 3, 2008, Pages 360-364

  McAlpine, J N ^a   Eisenkop, S M ^b   Spirtos, N M ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Women's Cancer Center Southern California   (United States)

^c UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; In vitro chemoresistance assays; Ovarian cancer; Tumor heterogeneity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; ASSAY; CANCER GRADING; CANCER STAGING; CELL HETEROGENEITY; EXTREME DRUG RESISTANCE ASSAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; PATHOLOGY; PRIORITY JOURNAL; TREATMENT FAILURE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; TAXOIDS; TOPOTECAN;

EID: 50149092407     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.05.019     Document Type: Article

References (33)

1. Bertelsen C.A., Korn E.I., Morton D.L., and Kern D.H. Heterogeneity of human metastatic clones by in vitro chemosensitivity testing. Implications for the clinical application of the clonogenic assay. Arch Surg 118 12 (1983 Dec) 1406-1409
2. Rustum Y.M., and Slocum H.K. Predictive tests for cancer chemotherapy and the problem of tumor cell heterogeneity. Prog Clin Biol Res 276 (1988) 119-137
3. Kimball R.E., Schlaerth J.B., Kute T.E., Schlaerth A.C., Santoso J., Ballon S.C., et al. Flow cytometric analysis of lymph node metastases in advanced ovarian cancer: clinical and biologic significance. American journal of obstetrics and gynecology 176 6 (1997 Jun) 1319-1326 [discussion 26-7]
4. Kern D.H., and Weisenthal L.M. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82 7 (1990 Apr 4) 582-588
5. Kern D.H., Bertelsen C.A., Mann B.D., Campbell M.A., Morton D.L., and Cochran A.J. Clinical application of the clonogenic assay. Ann Clin Lab Sci 13 1 (1983 Jan-Feb) 10-15
6. Cloven N.G., Kyshtoobayeva A., Burger R.A., Yu I.R., and Fruehauf J.P. In vitro chemoresistance and biomarker profiles are unique for histologic subtypesof epithelial ovarian cancer. Gynecologic oncology 92 1 (2004 Jan) 160-166
7. Arbuck S.G., Pavelic Z.P., Piver M.S., Slocum H.K., Malfetano J., Gamarra M., et al. Limitations of drug sensitivity testing in soft agar for clinical management of patients with ovarian carcinoma. Obstet Gynecol 66 (1985 Jul) 115-120
8. Tewari K.S., Mehta R.S., Burger R.A., Yu I.R., Kyshtoobayeva A.S., Monk B.J., et al. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecologic oncology 98 3 (2005 Sep) 360-368
9. Mehta R.S., Bornstein R., Yu I.R., Parker R.J., McLaren C.E., Nguyen K.P., et al. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast cancer research and treatment 66 3 (2001 Apr) 225-237
10. Korn E.L., Sondak V.K., Bertelsen C.A., and Kern D.H. Analysis of the clinical utility of a predictive chemosensitivity assay. Stat Med 4 4 (1985 Oct-Dec) 527-534
11. Orr Jr. J.W., Orr P., and Kern D.H. Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance. Cancer J Sci Am 5 3 (1999 May-Jun) 174-178
12. Holloway R.W., Mehta R.S., Finkler N.J., Li K.T., McLaren C.E., Parker R.J., et al. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients. Gynecologic oncology 87 1 (2002 Oct) 8-16
13. Eltabbakh G.H., Piver M.S., Hempling R.E., Recio F.O., Lele S.B., Marchetti D.L., et al. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecologic oncology 70 3 (1998 Sep) 392-397
14. Eltabbakh G.H. Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma. J Surg Oncol 73 3 (2000 Mar) 148-152
15. Ellis R.J., Fabian C.J., Kimler B.F., Tawfik O., Mayo M.S., Decelis C.R., et al. Factors associated with success of the extreme drug resistance assay in primary breast cancer specimens. Breast cancer research and treatment 71 2 (2002 Jan) 95-102
16. Shoemaker R.H., Wolpert-DeFilippes M.K., Kern D.H., Lieber M.M., Makuch R.W., Melnick N.R., et al. Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45 5 (1985 May) 2145-2153
17. Sondak V.K., Bertelsen C.A., Kern D.H., and Morton D.L. Evolution and clinical application of a rapid chemosensitivity assay. Cancer 55 6 (1985 Mar 15) 1367-1371
18. Sondak V.K., Korn E.L., Morton D.L., and Kern D.H. Testing chemotherapeutic combinations in the Human Tumor Colony-Forming Assay. J Surg Oncol 37 3 (1988 Mar) 156-160
19. Weisenthal L.M., and Kern D.H. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays. Oncology (Williston Park) 5 9 (1991 Sep) 93-103 [disc 4, 11-4, 17-8]
20. Schlag P., and Flentje D. Chemosensitivity testing of human neoplasms using the soft agar colony assay. Cancer Treat Rev 11 Suppl A (1984 Mar) 131-137
21. Parker R.J., Fruehauf J.P., Mehta R., Filka E., and Cloughesy T. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol 66 3 (2004 Feb) 365-375
22. Greenlee R.T., Hill-Harmon M.B., Murray T., and Thun M. Cancer statistics, 2001. CA Cancer J Clin 51 1 (2001 Jan-Feb) 15-36
23. Rubin S.C., Randall T.C., Armstrong K.A., Chi D.S., and Hoskins W.J. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol 93 1 (1999 Jan) 21-24
24. Holschneider C.H., and Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19 1 (2000 Jul-Aug) 3-10
25. Marie J.P., Zittoun R., and Sikic B.I. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 78 3 (1991 Aug 1) 586-592
26. Fisher G.A., and Sikic B.I. Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9 2 (1995 Apr) 363-382
27. Cortazar P., and Johnson B.E. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 17 5 (1999 May) 1625-1631
28. Fruehauf J.P. In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocrine-related cancer 9 3 (2002 Sep) 171-182
29. Fruehauf J.P., and Alberts D.S. Assay-assisted treatment selection for women with breast or ovarian cancer. Recent results in cancer research Fortschritte der Krebsforschung 161 (2003) 126-145
30. Schrag D., Garewal H.S., Burstein H.J., Samson D.J., Von Hoff D.D., and Somerfield M.R. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22 17 (2004 Sep 1) 3631-3638
31. Sevin B.U., and Perras J.P. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer. American journal of obstetrics and gynecology 176 4 (1997 Apr) 759-766 [discussion 66-8]
32. Havrilesky L., Darcy M., Hamdan H., Priore R.L., Leon J., Bell J., et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21 20 (2003 Oct 15) 3814-3825
33. Secord A.A., Lee P.S., Darcy K.M., Havrilesky L.J., Grace L.A., Marks J.R., et al. Maspin expression in epithelial ovarian cancer and associations with poor prognosis: a Gynecologic Oncology Group study. Gynecologic oncology 101 3 (2006 Jun) 390-397